Abstract:INTRODUCTION Despite advances in the understanding of the pathophysiology of the disease, clinical outcomes and quality of life of individuals with heart failure with preserved ejection fraction (HFpEF) remain poor. The role of a comorbidity-driven systemic inflammation has emerged as an important mechanism involved in profibrotic activation in HFpEF, and therefore as a promising therapeutic target in this setting. Inflammation also promotes myocardial damage due to epicardial coronary artery disease (CAD), coronary microvascular dysfunction (CMD), or both, thus reinforcing its role as a potential therapeutic target in patients with HFpEF in whom currently approved therapies are not aimed at reducing inflammation. Colchicine is an anti-inflammatory agent that has shown benefits in CAD. In HFpEF, colchicine may improve fibrosis through inhibition of inflammatory pathway implicated in both myocardial damage and CAD/CMD progression. HYPOTHESIS We hypothesize that colchicine, compared to placebo, will reduce circulating levels of biomarkers of inflammation in patients with HFpEF. Secondary questions include the effects of colchicine on biomarkers of hemodynamic stress and myocardial damage, CMD and functional status. Two dosing regimens will be compared as there is no data that have validated the appropriate dose of colchicine for HF indications. METHODS In a randomized, blinded, multiple-dose placebo-controlled clinical trial, we aim to study the effects of colchicine on inflammation in patients with HFpEF. The primary endpoint will be the change between baseline and 6 months in high-sensitivity C-reactive protein with colchicine vs. placebo. Secondary objectives will be the change between baseline and 6 months in 1) NT-pro brain natriuretic peptide and high sensitivity troponin and 2) coronary flow reserve, a marker of CMD, assessed using adenosine-based positron emission tomography imaging. Tertiary objectives will be the change between baseline and 6 months in NYHA class and six-minute walk test. A total of 426 participants will be randomly assigned in a 1:1:1 ratio to receive a 6-month course of colchicine at a dose of 0.5mg twice daily (high dose arm providing maximal inflammatory inhibition), colchicine at a dose of 0.5mg once daily (low dose arm as in CAD trials), or placebo. Follow-up will occur at 3 and 6 months after randomization. Recruitment will occur through an existing HF collaboration across Québec. EXPECTED OUTCOMES The causal role of a comorbidity-driven systemic pro-inflammatory state has recently emerged as an important mechanism involved in HFpEF, and therefore as a promising therapeutic target in this setting. This study is aimed at validating the proinflammatory/profibrotic hypothesis in HFpEF using colchicine, an anti-inflammatory medication. We expect that colchicine, on a background of standard of care, will allow for a significant reduction in circulating markers of inflammation and myocardial damage in patients with HFpEF. We also expect an improvement in CMD and functional status in patients treated with colchicine.

Colchicine-intolerant familial mediterranean fever patients: A comparative study between different colchicine doses and IL-1 inhibitor monotherapy

Factors Associated With Successful Withdrawal of Biologic Agents in Children With Colchicine-Resistant Familial Mediterranean Fever

Treatment Indications and Clinical Features in a Large Real-World Cohort

Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF

Colchicine Modulates Oxidative Stress in Serum and Leucocytes from Remission Patients with Family Mediterranean Fever Through Regulation of Ca2+ Release and the Antioxidant System

Gray zone in the spectrum of autoinflammatory diseases: familial Mediterranean fever accompanying periodic fever, aphthous stomatitis, pharyngitis, and adenitis syndrome: single-center experience

Inflammatory biomarker analysis confirms reduced disease severity in heterozygous patients with familial Mediterranean fever

Colchicine – an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants

Could tocilizumab be used in familial Mediterranean fever? A systematic review

The safety and feasibility of colchicine uptitration in the management of idiopathic recurrent pericarditis

Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever – a randomized controlled noninferiority trial

Canakinumab treatment in children with familial Mediterranean fever: report from a single center

The clinical role of anakinra in the armamentarium against familial Mediterranean fever

Mesothelioma in Familial Mediterranean Fever With Colchicine Intolerance: A Case Report and Literature Review

Interleukin-21 and Interleukin-23 levels in familial Mediterranean Fever before and after treatment: the role of cytokines in disease pathogenesis

α9β1 integrin & its ligands as new potential biomarkers in FMF

Colchicine in acutely decompensated heart failure: the COLICA trial

Colchicine in acute heart failure: Rationale and design of a randomized double‐blind placebo‐controlled trial (COLICA)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever

Effects Of Colchicine On Inflammation, Myocardial Damage And Microvascular Dysfunction In Men And Women With Heart Failure With Preserved Ejection Fraction

Colitis in a patient with familial Mediterranean fever: Is it Crohn's disease or ulcerative colitis?